We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+17%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$9.33B
AUM Growth
+$1.78B
Cap. Flow
+$552M
Cap. Flow %
5.91%
Top 10 Hldgs %
20.52%
Holding
814
New
78
Increased
378
Reduced
271
Closed
33

Top Buys

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$50.3M
2
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$39.4M
3
INTC icon
Intel
INTC
+$29.2M
4
QCOM icon
Qualcomm
QCOM
+$27.6M
5
DHR icon
Danaher
DHR
+$26M

Top Sells

Rank Stock Value
1
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$49.9M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$41.6M
3
ARQL
Arqule Inc
ARQL
+$26.5M
4
ARWR icon
Arrowhead Research
ARWR
+$24.9M
5
MRK icon
Merck
MRK
+$15.4M

Sector Composition

Rank Sector Weight
1 Healthcare 30.73%
2 Technology 19.55%
3 Financials 10.18%
4 Consumer Discretionary 9.32%
5 Communication Services 8.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MSFT icon
1
Microsoft
MSFT
$2.95T
$343M 3.67%
2,172,896
+342,489
+19% +$50.3M
AMGN icon
2
Amgen
AMGN
$198B
$218M 2.34%
904,948
-3,432
-0.4% -$757K
GOOGL icon
3
Alphabet (Google) Class A
GOOGL
$4.24T
$213M 2.29%
3,183,900
+611,340
+24% +$39.4M
AAPL icon
4
Apple
AAPL
$4.81T
$201M 2.16%
2,740,716
+95,844
+4% +$6.17M
BABA icon
5
Alibaba
BABA
$283B
$170M 1.83%
803,160
+34,517
+4% +$6.48M
BMY icon
6
Bristol-Myers Squibb
BMY
$124B
$160M 1.72%
2,498,642
-122,364
-5% -$7.01M
VRTX icon
7
Vertex Pharmaceuticals
VRTX
$122B
$159M 1.7%
725,361
-205,638
-22% -$41.6M
REGN icon
8
Regeneron Pharmaceuticals
REGN
$70.5B
$154M 1.65%
411,211
-963
-0.2% -$324K
AMZN icon
9
Amazon
AMZN
$2.66T
$149M 1.6%
1,611,000
+19,580
+1% +$1.73M
GILD icon
10
Gilead Sciences
GILD
$162B
$147M 1.57%
2,256,962
+10,067
+0.4% +$656K
MRK icon
11
Merck
MRK
$312B
$127M 1.36%
1,460,403
-186,921
-11% -$15.4M
PG icon
12
Procter & Gamble
PG
$345B
$119M 1.27%
952,251
+54,013
+6% +$6.61M
BIIB icon
13
Biogen
BIIB
$30B
$117M 1.25%
394,265
-44,324
-10% -$12.3M
META icon
14
Meta Platforms (Facebook)
META
$1.63T
$115M 1.23%
560,106
+22,843
+4% +$4.42M
DIS icon
15
Walt Disney
DIS
$167B
$91.4M 0.98%
631,644
+151,060
+31% +$21.1M
TSM icon
16
TSMC
TSM
$2.2T
$84.4M 0.9%
1,453,093
+182,215
+14% +$9.66M
JPM icon
17
JPMorgan Chase
JPM
$918B
$78.4M 0.84%
562,160
+182,387
+48% +$23.4M
CSCO icon
18
Cisco
CSCO
$442B
$74.7M 0.8%
1,556,669
+72,773
+5% +$3.38M
ILMN icon
19
Illumina
ILMN
$29.1B
$74M 0.79%
229,276
-40,105
-15% -$12.2M
V icon
20
Visa
V
$677B
$72.3M 0.78%
384,930
-6,629
-2% -$1.19M
ABBV icon
21
AbbVie
ABBV
$452B
$65.7M 0.7%
742,021
-122,092
-14% -$10.1M
UNH icon
22
UnitedHealth
UNH
$396B
$65.2M 0.7%
221,653
+4,647
+2% +$1.22M
C icon
23
Citigroup
C
$223B
$65.1M 0.7%
814,779
+252,405
+45% +$18.6M
PEP icon
24
PepsiCo
PEP
$184B
$63M 0.68%
461,309
+64,960
+16% +$8.84M
ALXN
25
DELISTED
Alexion Pharmaceuticals
ALXN
$62.3M 0.67%
575,794
-55,972
-9% -$5.99M
1
2 3 4 5

Similar funds

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
A
AustralianSuper Melbourne, Australia $19.2B AUM 31.95% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $19.1B AUM 26.9% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return

Candriam SCA's Q4 2019 Portfolio in Review

As of Q4 2019, Candriam SCA held 814 positions worth $9.33B, up 24% from $7.55B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

Candriam SCA deployed $552M of net new capital in Q4 2019, opening 78 new positions and adding to 378 existing holdings. Its largest new stake was Vipshop: 2,005,000 shares worth $28.4M.

By sector, the portfolio is most concentrated in Healthcare at 31% of assets, down from 32% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Ra Pharmaceuticals, Inc. Common Stock, an estimated $49.9M trimmed.

  • Candriam SCA's largest Q4 2019 buy was Vipshop: 2,005,000 shares worth $28.4M.
  • Candriam SCA added most to Microsoft in Q4 2019, an estimated $50.3M increase.
  • Candriam SCA's biggest Q4 2019 reduction was Ra Pharmaceuticals, Inc. Common Stock, cutting an estimated $49.9M.
  • Candriam SCA fully exited Hilton Worldwide in Q4 2019, selling an estimated $11.8M.
  • Candriam SCA's ten largest holdings make up 21% of its $9.33B portfolio in Q4 2019.
  • Candriam SCA opened 78 new positions and closed 33 in Q4 2019.
  • Candriam SCA's portfolio value rose 24% quarter-over-quarter to $9.33B.

Based on Candriam SCA's 13F filing for Q4 2019, filed 21 Jan 2020.